Stockreport

Data from Agios’ Phase 3 ClarIDHy Trial of TIBSOVO® Demonstrates Significant Improvement in Progression Free Survival (PFS) Compared to Placebo in Previously Treated IDH1 Mutant Cholangioc...

Agios Pharmaceuticals, Inc.  (AGIO) 
Last agios pharmaceuticals, inc. earnings: 4/30 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: investor.agios.com/investor-overview
PDF – TIBSOVO® Reduced the Risk of Disease Progression or Death by 63% (HR=0.37, p® was 2.7 months Compared to 1.4 Months with Placebo – – TIBSOVO® Patients Had 6-month PFS [Read more]